Drug Pricing & Access
Expert articles and analysis related to drug pricing & access.
AI Summary — Last 24 Hours
CMS’s GENEROUS Model remains the key drug-pricing development for VBC stakeholders: Medicaid savings potential is still highly uncertain because existing Medicaid rebates already substantially reduce net drug costs, and the model’s impact will depend on confidential or unresolved design details such as participating drugs, supplemental rebate terms, and state uptake (KFF analysis). At the same time, CMS’s proposed rule on drug prior authorization is drawing scrutiny because tighter federal parameters could affect payer utilization-management levers, with implications for Medicaid/MA plans, ACO-aligned prescribing workflows, and pharmacy-cost accountability in risk-based contracts ([Health Affairs](https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUTFtYlU4bkZzQ0ZDWFA2a3BzWlZsd0lZTUJOQ1dkZlBfN2Vrd1kzbzdzZ2dhUXVLQkttU0xZVmk2dnBvalpDaWoxODVnaTBiMkcxaERpc3ZGVDRPUU91YkJpRmxJY3lxM1J2Sm5pZmxZM29nMFA2d1N0WHFudmJuUGhUR2Y5Uml6dUcx
Related Articles
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on m...
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2025 - Office of Inspector General (.gov)
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2025 Office of Inspector General (.gov)
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.
A Look at the GENEROUS Model and the Potential Impact on Medicaid Drug Costs
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
new KFF issue brief
From newsletter: Several Factors Make it Difficult to Assess the Likely Impact of the GENEROUS Model on Medicaid Drug Costs Several Factors Make it Difficult to Assess the Likely Impact of the GENER...
Read the analysis
From newsletter: Several Factors Make it Difficult to Assess the Likely Impact of the GENEROUS Model on Medicaid Drug Costs Several Factors Make it Difficult to Assess the Likely Impact of the GENER...
Amazon Pharmacy debuts Ozempic pill delivery and in-office pickup
Amazon Pharmacy announced it will offer pharma giant Novo Nordisk's Ozempic pill, which received FDA approval earlier this year, for home delivery or pickup via an in-office kiosk through its digital ...
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep
Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular dy...